Galmed Pharmaceuticals (GLMD) Net Equity Issued and Repurchased (2014 - 2025)

Galmed Pharmaceuticals' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $7.5 million for Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to $7.5 million; the TTM figure through Dec 2025 stood at $3.6 billion (changed N/A YoY), while the FY2025 annual figure was $7.7 million, up 74.87% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $7.5 million, up from -$4.9 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $3.6 billion in Q2 2025, with the low at -$8.1 million in Q3 2021.
• The 5-year median for Net Equity Issued and Repurchased is $4.4 million (2024), against an average of $400.9 million.
• The sharpest annual moves came in 2022 and 2025: Net Equity Issued and Repurchased changed 0.0% in 2022, then tumbled 211.95% in 2025.
• Galmed Pharmaceuticals' Net Equity Issued and Repurchased stood at -$8.1 million in 2021, then soared by 313.18% to $17.4 million in 2022, then sank by 135.04% to -$6.1 million in 2023, then surged by 172.31% to $4.4 million in 2024, then surged by 70.36% to $7.5 million in 2025.
• Business Quant data shows GLMD's Net Equity Issued and Repurchased at $7.5 million in Q4 2025, -$4.9 million in Q3 2025, and $3.6 billion in Q2 2025.